The objective of the study is to assess the safety and efficacy of ANG-3777 in preventing AKI compared to placebo when administered to patients at risk for developing acute kidney injury (AKI) following cardiac surgical procedures involving cardiopulmonary bypass (CPB).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
275
The mean AUC of the percent increase in serum creatinine above baseline
Time frame: starting from 24 hr after the end of CPB through Day 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Southern California
Los Angeles, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Stanford University Medical Center
Palo Alto, California, United States
California Institute of Renal Reseach
San Diego, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Fleming Island Center for Clinical Research
Fleming Island, Florida, United States
UF Health at Unviersity of Florida
Gainesville, Florida, United States
River City Clinical Research
Jacksonville, Florida, United States
Indiana Ohio Heart
Fort Wayne, Indiana, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
...and 30 more locations